Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Free Cash Flow data on record, last reported at -$24.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 67.47% year-over-year to -$24.0 million; the TTM value through Dec 2025 reached -$276.9 million, down 18.92%, while the annual FY2025 figure was -$276.9 million, 18.92% down from the prior year.
  • Free Cash Flow reached -$24.0 million in Q4 2025 per VRDN's latest filing, up from -$84.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$11.5 million in Q1 2021 and bottomed at -$92.7 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$42.2 million, with a median of -$38.7 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 193.41% in 2023, then surged 67.47% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$16.5 million in 2021, then tumbled by 110.67% to -$34.8 million in 2022, then fell by 11.72% to -$38.9 million in 2023, then crashed by 89.73% to -$73.8 million in 2024, then soared by 67.47% to -$24.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$24.0 million in Q4 2025, -$84.9 million in Q3 2025, and -$75.3 million in Q2 2025.